Regulus Therapeutics (RGLS) Soars: Stock Rises 6.6% – Tale of the Tape

ZacksRegulus Therapeutics Inc. (RGLS) was a big mover last session, as its shares rose almost 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company since Oct 21, as the stock is now up over 34%.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Regulus Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other well-performing stocks in the med-drugs industry include IGI, Laboratories, Inc. (IG), Lannett Company, Inc. (LCI) and Portola Pharmaceuticals, Inc. (PTLA). All three carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply